Rezolute (RZLT) Competitors

$3.40 +0.07 (+2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$3.40 0.00 (-0.15%)

As of 04:58 PM Eastern

RZLT vs. COLL, MLTX, CALT, MPLT, and XERS

Should you buy Rezolute stock or one of its competitors? MarketBeat compares Rezolute with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rezolute include Collegium Pharmaceutical (COLL), MoonLake Immunotherapeutics (MLTX), Calliditas Therapeutics AB (publ) (CALT), Maplight Therapeutics (MPLT), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does Rezolute compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Collegium Pharmaceutical has a net margin of 9.41% compared to Rezolute's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Rezolute	N/A	-55.90%	-51.71%

Collegium Pharmaceutical has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$796.33M	1.42	$62.87M	$2.04	17.07
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Collegium Pharmaceutical has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

83.0% of Rezolute shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Collegium Pharmaceutical currently has a consensus price target of $57.50, suggesting a potential upside of 65.09%. Rezolute has a consensus price target of $8.75, suggesting a potential upside of 157.35%. Given Rezolute's higher possible upside, analysts clearly believe Rezolute is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rezolute	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Rezolute. MarketBeat recorded 10 mentions for Collegium Pharmaceutical and 8 mentions for Rezolute. Rezolute's average media sentiment score of 0.98 beat Collegium Pharmaceutical's score of 0.54 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Collegium Pharmaceutical beats Rezolute on 10 of the 15 factors compared between the two stocks.

How does Rezolute compare to MoonLake Immunotherapeutics?

Rezolute (NASDAQ:RZLT) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Rezolute has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 19 more articles in the media than Rezolute. MarketBeat recorded 27 mentions for MoonLake Immunotherapeutics and 8 mentions for Rezolute. Rezolute's average media sentiment score of 0.98 beat MoonLake Immunotherapeutics' score of 0.59 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	7 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute presently has a consensus price target of $8.75, indicating a potential upside of 157.35%. MoonLake Immunotherapeutics has a consensus price target of $23.85, indicating a potential upside of 29.67%. Given Rezolute's stronger consensus rating and higher probable upside, analysts clearly believe Rezolute is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Rezolute's return on equity of -55.90% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-55.90%	-51.71%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

83.0% of Rezolute shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Rezolute beats MoonLake Immunotherapeutics on 9 of the 13 factors compared between the two stocks.

How does Rezolute compare to Calliditas Therapeutics AB (publ)?

Rezolute (NASDAQ:RZLT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Rezolute has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Rezolute's return on equity of -55.90% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-55.90%	-51.71%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Rezolute presently has a consensus price target of $8.75, indicating a potential upside of 157.35%. Given Rezolute's stronger consensus rating and higher probable upside, analysts clearly believe Rezolute is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Rezolute. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

83.0% of Rezolute shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rezolute has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, Rezolute had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Rezolute and 0 mentions for Calliditas Therapeutics AB (publ). Rezolute's average media sentiment score of 0.98 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Rezolute is being referred to more favorably in the media.

Company	Overall Sentiment
Rezolute	Positive
Calliditas Therapeutics AB (publ)	Neutral

Summary

Rezolute beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Rezolute compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Rezolute (NASDAQ:RZLT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

In the previous week, Maplight Therapeutics had 12 more articles in the media than Rezolute. MarketBeat recorded 20 mentions for Maplight Therapeutics and 8 mentions for Rezolute. Rezolute's average media sentiment score of 0.98 beat Maplight Therapeutics' score of 0.13 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	9 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maplight Therapeutics' return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Rezolute	N/A	-55.90%	-51.71%

Rezolute is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Maplight Therapeutics presently has a consensus price target of $34.43, indicating a potential upside of 17.54%. Rezolute has a consensus price target of $8.75, indicating a potential upside of 157.35%. Given Rezolute's higher possible upside, analysts clearly believe Rezolute is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Rezolute	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

83.0% of Rezolute shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Maplight Therapeutics beats Rezolute on 7 of the 13 factors compared between the two stocks.

How does Rezolute compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Xeris Biopharma has a net margin of 3.81% compared to Rezolute's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Rezolute	N/A	-55.90%	-51.71%

Xeris Biopharma presently has a consensus price target of $10.80, indicating a potential upside of 69.28%. Rezolute has a consensus price target of $8.75, indicating a potential upside of 157.35%. Given Rezolute's stronger consensus rating and higher possible upside, analysts plainly believe Rezolute is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Rezolute	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Xeris Biopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

In the previous week, Xeris Biopharma had 7 more articles in the media than Rezolute. MarketBeat recorded 15 mentions for Xeris Biopharma and 8 mentions for Rezolute. Rezolute's average media sentiment score of 0.98 beat Xeris Biopharma's score of 0.58 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$314.85M	3.50	$550K	$0.06	106.33
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Xeris Biopharma beats Rezolute on 9 of the 15 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RZLT vs. The Competition

Export

Metric	Rezolute	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$325.37M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-4.15	18.81	20.87	25.58
Price / Sales	N/A	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.83	6.74	9.86	6.70
Net Income	-$74.41M	$24.11M	$3.55B	$333.77M
7 Day Performance	10.03%	0.07%	-0.32%	0.45%
1 Month Performance	-4.76%	0.84%	1.34%	4.06%
1 Year Performance	-2.58%	78.10%	41.03%	36.21%

Rezolute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RZLT Rezolute	2.7532 of 5 stars	$3.40 +2.1%	$8.75 +157.4%	-9.3%	$325.37M	N/A	N/A	40	Earnings Report Analyst Forecast Analyst Revision Gap Up
COLL Collegium Pharmaceutical	2.8171 of 5 stars	$35.81 -5.3%	$57.50 +60.6%	+17.0%	$1.23B	$780.57M	17.55	210	Earnings Report
MLTX MoonLake Immunotherapeutics	3.4226 of 5 stars	$18.84 +10.4%	$23.85 +26.6%	-52.2%	$1.22B	N/A	N/A	2	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up High Trading Volume
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
MPLT Maplight Therapeutics	2.2579 of 5 stars	$30.09 +9.8%	$34.43 +14.4%	N/A	$1.17B	N/A	N/A	109	Earnings Report Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RZLT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rezolute (RZLT) Competitors

RZLT vs. COLL, MLTX, CALT, MPLT, and XERS

How does Rezolute compare to Collegium Pharmaceutical?

Summary

How does Rezolute compare to MoonLake Immunotherapeutics?

Summary

How does Rezolute compare to Calliditas Therapeutics AB (publ)?

Summary

How does Rezolute compare to Maplight Therapeutics?

Summary

How does Rezolute compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rezolute (RZLT) Competitors

RZLT vs. COLL, MLTX, CALT, MPLT, and XERS

How does Rezolute compare to Collegium Pharmaceutical?

Is COLL or RZLT more profitable?

Which has stronger earnings and valuation, COLL or RZLT?

Which has more volatility & risk, COLL or RZLT?

Do insiders & institutionals hold more shares of COLL or RZLT?

Do analysts prefer COLL or RZLT?

Does the media favor COLL or RZLT?

Summary

How does Rezolute compare to MoonLake Immunotherapeutics?

Which has preferable valuation and earnings, RZLT or MLTX?

Which has more risk and volatility, RZLT or MLTX?

Does the media refer more to RZLT or MLTX?

Do analysts rate RZLT or MLTX?

Is RZLT or MLTX more profitable?

Do institutionals & insiders believe in RZLT or MLTX?

Summary

How does Rezolute compare to Calliditas Therapeutics AB (publ)?

Is RZLT or CALT more profitable?

Do analysts rate RZLT or CALT?

Which has preferable valuation and earnings, RZLT or CALT?

Do institutionals & insiders believe in RZLT or CALT?

Which has more risk and volatility, RZLT or CALT?

Does the media refer more to RZLT or CALT?

Summary

How does Rezolute compare to Maplight Therapeutics?

Does the media prefer MPLT or RZLT?

Is MPLT or RZLT more profitable?

Which has better valuation & earnings, MPLT or RZLT?

Do analysts recommend MPLT or RZLT?

Do insiders and institutionals believe in MPLT or RZLT?

Summary

How does Rezolute compare to Xeris Biopharma?

Is XERS or RZLT more profitable?

Do analysts recommend XERS or RZLT?

Which has more volatility and risk, XERS or RZLT?

Does the media prefer XERS or RZLT?

Which has preferable valuation and earnings, XERS or RZLT?

Do institutionals and insiders believe in XERS or RZLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools